THEUER CHARLES 4
4 · 4D Molecular Therapeutics, Inc. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
4D Molecular (FDMT) Director Charles Theuer Receives 50,000-Share Award
What Happened
Charles Theuer, a director of 4D Molecular Therapeutics, was granted a derivative award covering 50,000 shares on June 17, 2026. The Form 4 lists the acquisition price as $0.00 (reported value $0), indicating a grant of equity (stock options) rather than a cash purchase or sale. This is a compensation award under the company’s non-employee director program and is routine director compensation, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (appears timely).
- Grant: 50,000-share derivative award (stock option); transaction price shown as $0.00.
- Vesting: 1/3 vests on June 17, 2027 and then in equal monthly installments until fully vested on June 17, 2029; options vest in full upon a Change in Control. (Footnotes F1 and F2)
- Shares owned after transaction: not stated in the provided excerpt of the filing.
- Nature: Award/grant under non-employee director compensation (routine); no 10b5-1, tax withholding, or late-filing flags noted in the excerpt.
Context
This was a compensation grant (derivative stock option award) for a non-employee director — common practice for board pay. For retail investors, grants signal executive/director alignment with shareholders but are routine and do not necessarily indicate near-term insider confidence. The filing does not show an exercise price or immediate sale of shares; exercise terms and any future stock purchases would be reported separately when exercised or sold.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-17+50,000→ 50,000 totalExercise: $9.42Exp: 2036-06-16→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- [F2]The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).